Diabetic Retinopathy Market Hits $ USD 10.11 Billion By 2022: Grand View Research, Inc. by Andrew Smith

Diabetic Retinopathy Market By Type (Proliferative DR, Non-Proliferative DR) By Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy) Is Expected To Reach USD 10.11 Billion By 2022: Grand View Research, Inc.

Global Diabetic Retinopathy Market is expected to reach USD 10.11 billion by 2022, according to a new study by Grand View Research Inc. Diabetic retinopathy is considered as a serious sight threatening complication that results due to long term diabetes. The treatment line selection for diabetic retinopathy depends on the severity of the condition and may require intraocular injections, anti VEGF drugs, laser surgery or vitrectomy. Increasing incidences of diabetes, rising geriatric population base and the growing demand for early detection are some high impact rendering drivers of the diabetic retinopathy market. Furthermore, improving healthcare infrastructure, rising demand for cost-effective and safe treatment and rising focus of market players on emerging nations such as India and China are also anticipated to propel market growth. Presence of supportive government initiatives such as the Queen Elizabeth Diamond Jubilee Trust, which is taking initiatives for increasing patient awareness levels in order to promote regular retinal screening and early laser surgery to prevent permanent visual impairment and Ophthalmic Society of South Africa which works towards the improvement of reimbursement policies are anticipated to fuel the growth of the diabetic retinopathy market over the forecast period. View summary of this report analysis/diabetic-retinopathy-market

http://www.grandviewresearch.com/industry-

Global diabetic retinopathy market, by type, 2012-2022 (USD Million)

Table of Content Chapter 1 Methodology and Scope 1.1 Research Methodology 1.2 Research Scope & Assumptions 1.3 List of Data Sources Chapter 2 Executive Summary Chapter 3 Diabetic Retinopathy Industry Outlook 3.1 Market segmentation 3.2 Market size and growth prospects 3.3 Diabetic retinopathy market dynamics 3.4 Market driver analysis 3.4.1 Increasing prevalence of diabetes 3.4.2 Growing global geriatric population base 3.4.3 Increasing incidences of blindness due to diabetes 3.5 Market restraint analysis 3.5.1 Lack of accurate diagnosis 3.5.2 Extended approval time for drugs 3.5.3 Lack of trained ophthalmologists

3.6 Diabetic retinopathy: Epidemiology & guidelines 3.7 Diabetic retinopathy: Pipeline overview 3.8 Key Opportunities Prioritized 3.9 Diabetic retinopathy company market share, 2014 3.10 Industry analysis – Porter’s 3.11 Diabetic retinopathy PESTEL Analysis Chapter 4 Diabetic Retinopathy Type Outlook 4.1 Diabetic retinopathy revenue share by type, 2014 & 2022 4.2 Proliferative diabetic retinopathy 4.2.1 Proliferative diabetic retinopathy market, 2012 – 2022 (USD Million) 4.3 Non-proliferative diabetic retinopathy 4.3.1 Non-proliferative diabetic retinopathy market, 2012 – 2022 (USD Million) Chapter 5 Diabetic Retinopathy Management Outlook 5.1 Diabetic retinopathy revenue share, by management, 2014 & 2022 5.2 Anti-VEGF therapy 5.2.1 Anti-VEGF therapy market, 2012 – 2022 (USD Million) 5.3 Intraocular steroid injection 5.3.1 Intraocular steroid injection market, 2012 – 2022 (USD Million) 5.4 Laser surgery 5.4.1 Laser surgery market, 2012 – 2022 (USD Million) 5.5 Vitrectomy 5.5.1 Vitrectomy market, 2012 – 2022 (USD Million) Chapter 6 Diabetic Retinopathy Regional Outlook 6.1 Diabetic retinopathy revenue share, by region, 2014 & 2022 6.2 North America diabetic retinopathy market 6.2.1 North America diabetic retinopathy market, 2012 – 2022 (USD Million) 6.2.2 U.S. diabetic retinopathy market 6.2.2.1 U.S. diabetic retinopathy market, 2012 – 2022 (USD Million) 6.2.3 Canada diabetic retinopathy market 6.2.3.1 Canada diabetic retinopathy market, 2012 – 2022 (USD Million) 6.3 Europe diabetic retinopathy market 6.3.1 Europe diabetic retinopathy market, 2012 – 2022 (USD Million) 6.3.2 Germany diabetic retinopathy market 6.3.2.1 Germany diabetic retinopathy market, 2012 – 2022 (USD Million) 6.3.3 UK diabetics retinopathy 6.3.3.1 UK diabetic retinopathy market, 2012 – 2022 (USD Million) 6.4 Asia Pacific diabetic retinopathy market 6.4.1 Asia Pacific diabetic retinopathy market, 2012 – 2022 (USD Million)

6.4.2 China diabetic retinopathy market 6.4.2.1 China diabetic retinopathy market, 2012 – 2022 (USD Million) 6.4.3 Japan diabetic retinopathy market 6.4.3.1 Japan diabetic retinopathy market, 2012 – 2022 (USD Million) 6.5 Latin America diabetic retinopathy market 6.5.1 Latin America diabetic retinopathy market, 2012 – 2022 (USD Million) 6.5.2 Brazil diabetic retinopathy market 6.5.2.1 Brazil diabetic retinopathy market, 2012 – 2022 (USD Million) 6.6 MEA diabetic retinopathy market 6.6.1.1 MEA diabetic retinopathy market, 2012 – 2022 (USD Million) 6.6.2 South Africa diabetic retinopathy market 6.6.2.1 South Africa diabetic retinopathy market, 2012 – 2022 (USD Million) Chapter 7 Competitive Landscape 7.1 Bayer Healthcare 7.1.1 Company Overview 7.1.2 Financial Performance 7.1.3 Product Benchmarking 7.1.4 Strategic Initiatives 7.2 Novartis AG 7.2.1 Company Overview 7.2.2 Financial Performance 7.2.3 Product Benchmarking 7.2.4 Strategic Initiatives 7.3 Regeneron Pharmaceuticals Inc. 7.3.1 Company Overview 7.3.2 Financial Performance 7.3.3 Product Benchmarking 7.3.4 Strategic Initiatives 7.4 Actavis PLC 7.4.1 Company Overview 7.4.2 Financial Performance 7.4.3 Product Benchmarking 7.4.4 Strategic Initiatives 7.5 ThromboGenics 7.5.1 Company Overview 7.5.2 Financial Performance 7.5.3 Product Benchmarking 7.5.4 Strategic Initiatives

7.6 Sirnaomics Incorporation 7.6.1 Company Overview 7.6.2 Financial Performance 7.6.3 Product Benchmarking 7.7 Genentech 7.7.1 Company Overview 7.7.2 Financial Performance 7.7.3 Product Benchmarking 7.7.4 Strategic Initiatives 7.8 Glycadia Pharmaceuticals 7.8.1 Company Overview 7.8.2 Financial Performance 7.8.3 Product Benchmarking 7.9 Alimera Sciences 7.9.1 Company Overview 7.9.2 Financial Performance 7.9.3 Product Benchmarking 7.9.4 Strategic Initiatives 7.10 Ampio Pharmaceuticals 7.10.1 Company Overview 7.10.2 Financial Performance 7.10.3 Product Benchmarking 7.10.4 Strategic Initiatives 7.11 BCN Peptides 7.11.1 Company Overview 7.11.2 Financial Performance 7.11.3 Product Benchmarking 7.11.4 Strategic Initiatives 7.12 Kowa Group 7.12.1 Company Overview 7.12.2 Financial Performance 7.12.3 Product Benchmarking 7.12.4 Strategic Initiatives

Browse full report @ http://www.grandviewresearch.com/industry-analysis/diabeticretinopathy-market

List of Tables TABLE 1 Diabetic Retinopathy - Industry Snapshot & Key Buying Criteria, 2012-2022 TABLE 2 Global diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 3 Global diabetic retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 4 Global diabetic retinopathy market, by region, 2012 - 2022 (USD Million) TABLE 5 Diabetic retinopathy - Key market driver analysis TABLE 6 North America diabetes prevalence (national prevalence %), 2013 & 2035 TABLE 7 Europe diabetes prevalence (national prevalence %), 2013 & 2035 TABLE 8 Latin America diabetes prevalence (national prevalence %), 2013 & 2035 TABLE 9 MENA and Africa diabetes prevalence (national prevalence %), 2013 & 2035 TABLE 10 CIS diabetes prevalence (national prevalence %), 2013 & 2035 TABLE 11 Asia Pacific diabetes prevalence (national prevalence %), 2013 & 2035 TABLE 12 Diabetic retinopathy - Key market restraint analysis TABLE 13 Recent guidelines for diabetic retinopathy TABLE 14 Regional specific diabetes and diabetic retinopathy epidemiology TABLE 15 Diabetic retinopathy: Pipeline overview TABLE 16 North America diabetic retinopathy market, by region, 2012 - 2022 (USD Million) TABLE 17 North America diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 18 North America Diabetic Retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 19 U.S. diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 20 U.S. Diabetic Retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 21 Canada diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 22 Canada diabetic retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 23 Europe diabetic retinopathy market, by region, 2012 - 2022 (USD Million) TABLE 24 Europe diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 25 Europe diabetic retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 26 Germany diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 27 Germany diabetic retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 28 UK diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 29 UK diabetic retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 30 Asia Pacific diabetic retinopathy market, by region, 2012 - 2022 (USD Million) TABLE 31 Asia Pacific diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 32 Asia Pacific diabetic retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 33 China diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 34 China diabetic retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 35 Japan diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 36 Japan diabetic retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 37 Latin America diabetic retinopathy market, by region, 2012 - 2022 (USD Million) TABLE 38 Latin America diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 39 Latin America diabetic retinopathy market, by management, 2012 - 2022 (USD Million)

TABLE 40 Brazil diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 41 Brazil diabetic retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 42 MEA diabetic retinopathy market, by region, 2012 - 2022 (USD Million) TABLE 43 MEA diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 44 MEA diabetic retinopathy market, by management, 2012 - 2022 (USD Million) TABLE 45 South Africa diabetic retinopathy market, by type, 2012 - 2022 (USD Million) TABLE 46 South Africa diabetic retinopathy market, by management, 2012 - 2022 (USD Million)

For More Information visit http://www.grandviewresearch.com/industry-analysis/diabeticretinopathy-market

List of Figures FIG. 1 Diabetic Retinopathy: Market segmentation FIG. 2 Global diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 3 Diabetic retinopathy market dynamics FIG. 4 Diabetes prevalence of top 10 countries in 2013 in the age group of 20 to 79 years (million) FIG. 5 Current and projected prevalence of diabetes, by geography, 2013 & 2035 (% increase) FIG. 6 Rising geriatric population, by geography, 2013 & 2035 (% increase) FIG. 7 Growth in diabetic retinopathy cases according to age and gender (%) FIG. 8 Occurrence of blindness in diabetic patients, by age group (2009) (in percentage) FIG. 9 Ophthalmologist growth rate v/s population growth rate, 2010 FIG. 10 Key opportunities prioritized FIG. 11 Diabetic retinopathy company market share, 2014 FIG. 12 Diabetic retinopathy market Porterâ&#x20AC;&#x2122;s analysis FIG. 13 Diabetic retinopathy PESTEL analysis FIG. 14 Diabetic retinopathy revenue share by type, 2014 & 2022 FIG. 15 Proliferative diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 16 Non-proliferative diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 17 Diabetic retinopathy revenue share, by management, 2014 & 2022 FIG. 18 Anti-VEGF therapy market, 2012 - 2022 (USD Million) FIG. 19 Intraocular steroid injection market, 2012 - 2022 (USD Million) FIG. 20 Laser surgery market, 2012 - 2022 (USD Million) FIG. 21 Vitrectomy market, 2012 - 2022 (USD Million) FIG. 22 Diabetic retinopathy revenue share, by region, 2014 & 2022 FIG. 23 North America diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 24 U.S. diabetic retinopathy distribution, by age, 2012

FIG. 25 U.S. diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 26 Canada diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 27 Europe diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 28 Germany diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 29 UK diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 30 Asia Pacific diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 31 China diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 32 Japan diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 33 Latin America diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 34 Brazil diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 35 MEA diabetic retinopathy market, 2012 - 2022 (USD Million) FIG. 36 South Africa diabetic retinopathy market, 2012 - 2022 (USD Million)

Further key findings from the study suggest: 



Anti VEGF is identified as the most attractive sub segment of the diabetic retinopathy market, growing at a rate of over 6.0% over the forecast period owing to, the rising incidences of diabetes and high efficacy rates The non proliferative diabetic retinopathy segment accounted for the largest market share in 2014. The growing geriatric population and rising incidences of blindness caused due to diabetes are some key factors accounting for its large share. Furthermore, the increasing demand for regular retinal screening for long time diabetic patients is also expected to boost segment growth. The North American diabetic retinopathy market accounted for over 35.0% of the revenue in 2014 on account of, the presence of high diagnostic and therapeutic rates in the U.S. The rising patient awareness levels and the presence of favorable government initiatives encouraging regular retinal screening is expected to drive regional market growth. The Asia Pacific diabetic retinopathy market is likely to witness lucrative growth over the forecast period due to, the presence of unmet needs in the developing economies such as China and India. Presence of favorable government initiatives to enhance retinal screening rates and improving healthcare infrastructure are also expected to contribute towards rapid market growth. Some key players of the diabetic retinopathy market include Bayer Healthcare, Novartis AG, ThromboGenics, Regeneron Pharmaceuticals Inc., Actavis Plc, Alimera Sciences, BCN Peptides and Kowa Group

Request free sample of this Report @ http://www.grandviewresearch.com/industryanalysis/diabetic-retinopathy-market/request

For the purpose of this study, Grand View Research has segmented the global diabetic retinopathy market on the basis of type, management and region: Global Diabetic Retinopathy Type Outlook (Revenue, USD Million, 2012 – 2022)  

Proliferative Non proliferative

Global Diabetic Retinopathy Management Outlook (Revenue, USD Million, 2012 – 2022)    

Anti VEGF Intraocular steroid injection Laser surgery Vitrectomy

Diabetic Retinopathy Regional Outlook (Revenue, USD Million, 2012 – 2022) 



North America  U.S.  Canada Europe  Germany  UK  Rest of Europe Asia Pacific  Japan  China  Rest of Asia Pacific Latin America  Brazil  Rest of Latin America Middle East and Africa (MEA)  South Africa  Rest of Middle East and Africa

Browse

All

Reports

this

http://www.grandviewresearch.com/industry/medical-devices